Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Dec 2024 value amounting to $6.6 million.

  • Rhythm Pharmaceuticals' Gains from Investment Securities rose 677.31% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 975.93%. This contributed to the annual value of $6.6 million for FY2024, which is 0.92% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Gains from Investment Securities of $6.6 million as of FY2024, which was up 0.92% from $6.6 million recorded in FY2023.
  • Rhythm Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $6.6 million during FY2024, with a 5-year trough of $2.7 million in FY2020.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Gains from Investment Securities value was $6.6 million (recorded in 2023), while the average stood at $6.5 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Gains from Investment Securities fell by 22.39% in 2020, and later spiked by 115.62% in 2021.
  • Rhythm Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $2.7 million in 2020, then spiked by 115.62% to $5.7 million in 2021, then increased by 11.10% to $6.4 million in 2022, then rose by 2.77% to $6.6 million in 2023, then climbed by 0.92% to $6.6 million in 2024.